Make your money go further for just 25p per day

PREMIUM
AIM IHT

Fevertree: more than tonic, but how much more?

Fever-tree paloma

The world's leading supplier of premium carbonated mixers reassured with its full year results reporting strong growth in overseas markets and encouraging signs outside the key tonic category. But although management offered plenty of detail on the split of its business across various markets, they seem reluctant to provide certain key information which would give prospective investors a far better idea of the key drivers of the business.


For the year ending 31 December 2019, Fevertree Drinks (LON:FEVR) saw revenue rise 9.7% to £261m. Pre-tax profit fell 4% to £72.5m reflecting a weaker second half in the UK but also continuing investment in the business. At first glance, these results look far removed from the growth engine of old, which delivered revenue growth of 39% between 2017 and 2018 and 67% the year before as the UK basked in a gin & tonic boom.…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Fevertree Drinks

Episode 33 of the Investor’s Champion Podcast

15/09/2024 · Podcasts

In this episode of the Investors Champion Podcast, hosts Lee and Chris focus on news from…


US growth | Legal winner | Dividend delights

13/09/2024 · Company Insights

News covered here includes our assessment of interim results from Fevertree, which disappointed the market, despite…


More Company Insights

Stonking Small Caps: record results

22/10/2024 · PCI- PAL

Excellent results, but nobody is looking!

Fast-growing consulting firm acquires again

21/10/2024 · Elixirr International

Sign-up to our free email updates

SIGN UP